OM 8980

Known as: OM-8980

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

1994

OM-8980 is a slow-acting antirheumatic drug (SAARD). It is a glycoprotein extract of Escherichia coli, with immunomodulatory…

1993

Sixty patients with active RA were evaluated over 6 months in a double-blind randomized dose range multicentre study comparing…

Review

1993

Review

1993

The results obtained with Subreum®, a peptide extract of E. coli, given orally, as a slow acting antirheumatic drug are…

Review

1993

Review

1993

Although the pathogenesis of rheumatoid arthritis increasingly continues to be well understood, therapeutic approaches to the…

1991

OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the…

1990

SummaryA 6-month double-blind study of OM-8980 and auranofin in 145 patients with rheumatoid arthritis was followed by an open…

1990

Forty patients with active rheumatoid arthritis were included in this monocentre double-blind study comparing the therapeutic…

Highly Cited

1989

Highly Cited

1989

A new immunomodulating drug, OM-8980, was compared to placebo in a 6-month double blind multicenter trial including 107 patients…

1989

1988

The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold…